Form 7 Monthly Progress Report April 2024

biomark-progress-report

Form 7 Monthly Progress Report April 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 April 5th, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]

BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA

biomark-press-release

BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia – (April 9, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus […]

Form 7 Monthly Progress Report February 2024

biomark-progress-report

Form 7 Monthly Progress Report January 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 March 4th, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]

Theresa Peterson Joins BioMark’s Advisory Team

biomark-press-release

Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) an advanced-stage liquid biopsy company with a focus on hard-to-detect and treat cancers is pleased to announce that Mrs. Theresa Peterson as a new member of BioMark’s Advisory team. Mr. Rashid Ahmed Bux, CEO and President of […]

Form 7 Monthly Progress Report January 2024

biomark-progress-report

Form 7 Monthly Progress Report January 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 February 3, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]

BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT

biomark-press-release

BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia – (December 29th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed […]

Form 7 Monthly Progress Report December 2023

biomark-progress-report

Form 7 Monthly Progress Report December 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 January 1, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]

insightscare Interview: BioMark Diagnostics Inc: Innovating Cancer Detection

BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid A Bux | CEO and Founder | BioMark Diagnostics Inc A dynamic field like diagnostics requires efficient technologies for detecting diseases and critical illnesses. One organization that stands out with its innovative solutions in pursuit of this universal mission is BioMark […]